Novo Nordisk's (NOVOB DC) CagriSema 2.4 did not meet the primary endpoint of showing non-inferiority on weight loss vs tirzepatide 15mg at 84 weeks

Novo Nordisk's CagriSema trial results indicate a miss on its primary endpoint compared to tirzepatide, revealing a smaller weight loss effect.

Newsquawk StaffPublished 23 Feb 2026, 09:55 UTCOn the live feed at 09:35 UTC — 6 more headlines followed before this page went public

Newsquawk headlinesUTC

09:42

[MARKET ANALYSIS] WTI and Brent contained by Trump's tariffs with focus on US-Iran talks this week

09:36

[MARKET ANALYSIS] Fixed income relatively contained & awaiting further tariff updates

09:35

Novo Nordisk's (NOVOB DC) CagriSema 2.4 did not meet the primary endpoint of showing non-inferiority on weight loss vs tirzepatide 15mg at 84 weeks

09:05

Swiss Sight Deposits (w/e Feb 22). Domestic Banks CHF 440.6bln (prev. 437bln), Total CHF 457.6bln (prev. 452.7bln)

09:00

Italian Inflation Rate MoM Final (Jan) M/M 0.4% vs. Exp. 0.4% (Prev. 0.2%)

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Try the platform free

Free. No signup, no card.

CagriSema achieved 23% weight loss after 84 weeks of treatment, tirzepatide achieved 25.5%.
CagriSema 2.4/2.4 mg did not meet the primary endpoint of showing non-inferiority on weight loss compared to tirzepatide 15 mg at 84 weeks.
Additional trials are exploring the full weight loss potential of CagriSema, including higher-dose combinations.

Context

This could impact investor sentiment, as the effectiveness relative to competitors is crucial for market positioning. The ongoing trials for higher doses suggest the company may still have avenues to enhance CagriSema's profile, but immediate market reactions may lean negative.

All markets · last 90 days

Recent headlines that moved markets

METALS/1 Sep · 08:06

Two oil supertankers were reportedly hit by projectiles in the Strait of Hormuz, reports citing Marisks suggest (details light)

Spot Gold, after we published−1.0%

Further upside seen in energy, downside in equities and fixed and fresh USD strength following this. - Spot gold slipped to USD 4390/oz before dipping lower.

FX/28 Aug · 14:00

Fed Chair Warsh says Fed has more work to do unless confident underlying inflation is moving towards 2% objective

+0.5%DXY

ENERGY/27 Aug · 17:46

The Trump administration has repeatedly told mediators it has no interest in going back to the terms of the MoU it reached with Iran in June, reports WSJ citing sources

+1.4%Brent crude

EQUITIES/26 Aug · 12:56

States and Meta (META) and agree to settle claims that platforms harmed children, according to a court filing; Meta agrees to pay a maximum of USD 16.68bln to states as part of deal

+2.6%market

ENERGY/25 Aug · 19:26

A ceasefire between the US and Iran has been agreed upon, it includes free navigation in the Strait of Hormuz and will be announced in the coming days, reports Ria citing Pakistani and Iranian sources

−2.4%Brent crude

FX/2 Sep · 13:45

BoC holds rates as expected as 2.25%

−0.3%USD/CAD

Newsquawk Daily

Get both market opens in your inbox.

This note and the other one — the EU open and the US open, every business day, written by the desk. No account needed.

Related headlines

The whole workspace, free to try.

© 2026 Newsquawk. All rights reserved.